RAPH: Raphael Pharmaceutical Inc. Stock

by • Jul 1, 2019 • Comments Off on RAPH: Raphael Pharmaceutical Inc. Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M)	18.66
Enterprise Value ($M)	18.43
Book Value ($M)	0.27
Book Value / Share	0.01
Price / Book	69.89
NCAV ($M)	0.27
NCAV / Share	0.01
Price / NCAV	70.42

Profitability (mra)
Return on Invested Capital (ROIC)	-4.81
Return on Assets (ROA)	-8.56
Return on Equity (ROE)	n/a

Liquidity (mrq)
Quick Ratio	4.68
Current Ratio	4.68

Balance Sheet (mrq) ($M)
Current Assets	0.34
Assets	0.34
Liabilities	0.07
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	-1.27
Net Income	-1.28
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	-1.20
Cash from Investing	0.00
Cash from Financing	1.15
(click for more detail)

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-03-28	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REP
2023-08-09	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT P
2023-05-25	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPO
2023-05-15	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT
(click for more detail)

Similar Companies
PYRGF – PyroGenesis Canada Inc.	QBIO – Q BioMed Inc.
QRON – Qrons Inc.	RASP – Actavia Life Sciences, Inc.
RBSH – Rebus Holdings, Inc.

Financial data and stock pages provided by
Fintel.io